exceet Group SCA

  • WKN: A0YF5P
  • ISIN: LU0472835155
  • Land: Luxemburg

Nachricht vom 17.05.2021 | 17:25

exceet Group SCA: exceet prepares potential sale of Swiss company GS Swiss PCB AG

exceet Group SCA / Key word(s): Disposal/Disposal
exceet Group SCA: exceet prepares potential sale of Swiss company GS Swiss PCB AG

17-May-2021 / 17:25 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

Ad hoc Announcement

exceet prepares potential sale of Swiss company GS Swiss PCB AG

Grevenmacher, 17 May 2021 - The Board of Directors of exceet Group SCA ("exceet") today resolved to start a large-scale structured sales process with regards to the potential sale of its portfolio company GS Swiss PCB AG. In the financial year 2020, the manufacturer of highly miniaturized printed circuit boards for the medical technology and aerospace sectors based in the Swiss Canton of Schwyz generated revenues of EUR 36 million and an operating profit (EBITDA)1) of EUR 9.5 million. A decision as to whether and at which date the sale will take place has not yet been made.

1) Earnings before Interest, Taxes, Depreciation and Amortization (see pages 102 -105 "Alternative Performance Measures" of the Annual Report 2020

Further information:

Hendrik von Gregory
Email: investor.relations@exceet.com
exceet Group SCA
17, rue de Flaxweiler
L-6776 Grevenmacher
Telefon +352 28 38 47 20

ISIN: LU0472835155
Listed: Regulated Market of the Frankfurt Stock Exchange (Prime Standard)

About exceet
exceet is a listed holding company pursuing an opportunistic investment approach without a defined investment strategy. The investment focus is on seizing attractive risk / reward profiles without restrictions regarding the asset class, structure or duration of such investments.

17-May-2021 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de

show this

GBC im Fokus

IGEA Pharma N.V. Realignment to CBD extraction

The goal is to become the quality and cost leader in the field of CBD in Europe. To this end, a GMP pharma compliant plant is being built in Switzerland. The supercritical CO2 extraction process is to be used to achieve the highest standard of quality. The CBD market is growing strongly and with the focus on quality leadership and pure extraction, IGEA Pharma's new business model should be able to occupy an attractive niche market. With the proprietary supercritical CO2-extraction technology, other markets such as vanilla, rose or rosemary can be developed in the medium term. Based on our DCF model, we have determined a fair value of € 1.05 (CHF 1.13) per share and assign a BUY rating.

News im Fokus

Allianz SE: Allianz kündigt Abschluss eines Rückversicherungsvertrages in den USA an

03. Dezember 2021, 07:03

Aktueller Webcast

Deutsche Konsum REIT-AG

FY 2020/2021 Financial Results

16. Dezember 2021

Aktuelle Research-Studie

CEWE Stiftung & Co. KGaA

Original-Research: CEWE Stiftung & Co. KGaA (von GSC Research GmbH): Kaufen

02. Dezember 2021